Abbott’s next-generation Amulet LAA occlusion device earns CE Mark
August 27, 2026
Abbott’s (NYSE: ABT) Amulet 360 left atrial appendage (LAA) occlusion device received CE mark, the company announced today.
Abbott’s (NYSE: ABT) Amulet 360 left atrial appendage (LAA) occlusion device received CE mark, the company announced today.
Paradromics received FDA approval to expand the types of computing devices that could be used with its investigational brain-computer interface (BCI) system, the company told MassDevice.